Addex Therapeutics Ltd.
ADXNDrugs in Pipeline
3
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 1 past
No catalysts found.
ADX10059
Gastroesophageal Reflux
ADX48621
Parkinson's Disease
Dipraglurant
Blepharospasm
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
ADX10059 | Phase 2 | Gastroesophageal Reflux | - | - |
ADX48621 | Phase 2 | Parkinson's Disease | - | - |
Dipraglurant | Phase 2 | Blepharospasm | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Addex Therapeutics Ltd.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in Addex Therapeutics Ltd.'s (ADXN) pipeline across Phase 2. Its lead program is ADX10059 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Addex Therapeutics Ltd.'s next FDA catalyst?→
Addex Therapeutics Ltd.'s (ADXN) next tracked catalyst is a Earnings expected September 28, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ADXN biotech catalysts?→
Add ADXN to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Addex Therapeutics Ltd.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.